China: Privacy

China's revised Good Clinical Practice for Drug Trials took effect on 1 September 2026, fundamentally reshaping the regulatory landscape for clinical trials by aligning domestic requirements with ICH E6(R3) standards. The new framework introduces streamlined regulations spanning just 54 articles across six chapters, while establishing comprehensive data governance requirements and clarifying ultimate accountability for sponsors, principal investigators, and clinical trial institutions. Companies conducting

China's Q2 2026 regulatory landscape saw major developments across data privacy, foreign investment, intellectual property, and international trade. New measures operationalize network data security risk assessments, establish comprehensive outbound investment rules, revise trademark law to combat squatting, and introduce supply chain security frameworks with anti-extraterritorial jurisdiction countermeasures.

China's Supreme People's Court has issued its first comprehensive judicial guidance on artificial intelligence disputes, establishing how existing intellectual property...

China's cross-border data transfer regime has moved from paper framework to active enforcement in 2026, with regulators issuing significant fines and new rules for both small and large data processors. The three-pathway framework of CAC security assessment, Standard Contract filing, and personal information protection certification is now fully operational, creating real compliance obligations for any business moving personal data out of China.

2026年8月14日，上海市工商联数字经济商会、中国计算机行业协会与北京金诚同达（上海）律师事务所，共同举办“数智时代，共赴合规新篇”数智合规实践研讨会。我受邀作为主题分享嘉宾，坐在台下的，是来自各家企业的法务总监、合规负责人和企业管理者。

광시 지재권 전략실시업무사무실이 2026년 지재권 강구 건설 업무방안을 발표하며 지재권의 고품질 발전체계 구축, 고수준 보호, 고효율 전환 등 7개 분야 29개 &#